Publications
67
Citations
1,260
Est. group size
~1
Recurring co-author estimate
Active years
28
Publishing since 1998
Mark Ranalli's work focuses on pediatric oncology, particularly childhood kidney tumors (Wilms tumor), neuroblastoma, rhabdoid tumors, and acute lymphoblastic leukemia/lymphoma. His research spans clinical trials of new drug combinations, treatment guidelines, surgical outcomes, and studies on how children with cancer and their families experience symptoms and quality of life. This work is aimed at improving both survival and long-term wellbeing for children treated for cancer.
Publication output has been fairly steady over the last decade at roughly 3-5 papers per year, with a notable increase to 9 publications in 2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Differences in Symptom Reporting by Children With Cancer, Caregivers, and Care Teams
Journal of Pain and Symptom Management · 2025
- Wilms Tumor, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network · 2025
- Anti‐Tumor Activity of Paclitaxel‐Containing Regimens in Recurrent/Refractory Wilms Tumor
Pediatric Blood & Cancer · 2025
- Paternal Contributions to Biopsychosocial Outcomes of Children With Cancer: A Scoping Review
Pediatric Blood & Cancer · 2025
- A Single-Institution Analysis of Surveillance Practice for Low-Risk Neuroblastic Tumors
Journal of Surgical Research · 2025
- Understanding the influence of social determinants of health on symptom reporting in pediatric cancer
The Journal of Rural Health · 2025
- Rhabdoid tumor predisposition syndrome: A historical review of treatments and outcomes for associated pediatric malignancies
Pediatric Blood & Cancer · 2024
- Preliminary experience of ex-vivo expanded allogeneic universal donor TGFβi NK cell infusions in combination with irinotecan, temozolomide, and dinutuximab in patients with relapsed or refractory neuroblastoma: The Allo - STING trial.
Journal of Clinical Oncology · 2024
- Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial
The Lancet Haematology · 2023
- Variability in Surveillance Strategies Following Resection of Sacrococcygeal Teratoma
Journal of Surgical Research · 2023
- Apixaban Is Effective and Safe in Reducing Venous Thromboembolism (VTE) in Obese Patients with Newly Diagnosed Pediatric Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (ALL/LL) a Sub-Study Analysis of the Prevapix-ALL/Children's Oncology Group ACCL1333 Trial
Blood · 2023
- <scp><i>EGFR</i></scp> internal tandem duplications in fusion‐negative congenital and neonatal spindle cell tumors
Genes Chromosomes and Cancer · 2022
- Molecular Heterogeneity in Pediatric Malignant Rhabdoid Tumors in Patients With Multi-Organ Involvement
Frontiers in Oncology · 2022
- Utilizing a Quality Improvement Strategy to Increase Faculty Engagement With Resident Learning Goals
Academic Pediatrics · 2022
- Wilms Tumor (Nephroblastoma), Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2021
- Pediatric Blood & Cancer×6
- Journal of Surgical Research×4
- Journal of Pediatric Hematology/Oncology×3
- Neuro-Oncology×3
- Journal of the National Comprehensive Cancer Network×2
- Jennifer H. Aldrink
Medicine · The Ohio State University
- Jennifer Sturgis
Medicine · Purdue University West Lafayette
- A W Craft
Medicine · The Ohio State University
- Brian Weiss
Medicine · Indiana University
- Keri A. Streby
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile